STUDY COMPARISON OF EFFICACY OF LEVETIRACETAM AND MAGNESIUM SULPHATE IN THE MANAGEMENT OF ANTEPARTUM, INTRAPARTUM AND POSTPARTUM CONVULSIONS

A PROSPECTIVE STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LEVETIRACETAM IN COMPARISON TO MAGNESIUM SULPHATE IN THE MANAGEMENT OF ECLAMPSIA

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/04/032963

Enrollment

Registered

2021-04-20

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O159- Eclampsia, unspecified as to timeperiod

Interventions

Intervention1: LEVETIRACETAM: 1 G LOADING DOSE IV 500 MG BD MAINTENANCE DOSE IV IN 100 ML NS RELATIVELY SAFE TO BE USED IN PREGNANCY Control Intervention1: MAGNESIUM SULPHATE: PRITCHARDS REGIMEN. LOAD

Eligibility

Inclusion criteria

Inclusion criteria: ALL PATIENTS PRESENTING WITH FEATURES OF ECLAMPSIA DURING THE SAID PERIOD WILL BE RECRUITED INTO THE STUDY ALL PATIENTS GIVING INFORMED AND WRITTEN CONSENT FOR INVESTIGATIONS

Exclusion criteria

Exclusion criteria: PATIENTS WHO WERE DIAGNOSED WITH OTHER CAUSES OF CONVULSIONS IN PREGNANCY LIKE CEREBRAL MALARIA AND EPILEPSY CHRONIC HYPERTENSIVE PREGNANT FEMALES PREGNANT FEMALES WITH FETAL ANOMALIES DETECTED ON USG

Design outcomes

Primary

Measure	Time frame
TO OBSERVE FOR CONVULSIONS POST ANTIEPILEPTIC TREATMENT DURING THE PERIOD PATIENT IS IN HOSPITALTimepoint: DURATION OF HOSPITAL STAY (1-2 WEEKS)	—

Secondary

Measure	Time frame
NOT APPLICABLETimepoint: NOT APPLICABLE	—

Countries

India

Contacts

Public ContactDR SR BIDRI

Shri BM Patil Medical College

srbidri6@gmail.com9553223311

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026